Compare · CAI vs NTRA
CAI vs NTRA
Side-by-side comparison of Caris Life Sciences Inc. (CAI) and Natera Inc. (NTRA): market cap, price performance, sector, and recent activity on the wire.
Summary
- Both CAI and NTRA operate in Medical Specialities (Health Care), so they compete in similar markets.
- NTRA is the larger of the two at $41.98B, about 7.5x CAI ($5.59B).
- NTRA has been more active in the news (33 items in the past 4 weeks vs 4 for CAI).
- NTRA has more recent analyst coverage (25 ratings vs 16 for CAI).
- Company
- Caris Life Sciences Inc.
- Natera Inc.
- Price
- -
- -
- Market cap
- $5.59B
- $41.98B
- 1M return
- -
- -
- 1Y return
- -
- -
- Industry
- Medical Specialities
- Medical Specialities
- Exchange
- NASDAQ
- NASDAQ
- IPO
- 2025
- 2015
- News (4w)
- 4
- 33
- Recent ratings
- 16
- 25
Caris Life Sciences Inc.
CAI International, Inc. operates as a transportation finance company in the United States, Switzerland, France, Korea, Singapore, rest of Asia, rest of Europe, and internationally. The company leases, re-leases, and disposes equipment; and contracts for the repair, repositioning, and storage of equipment. It leases its container equipment to lessees under long-term, short-term, and finance leases. The company also sells containers; and manages equipment for to third-party investors, as well as sells used containers. As of December 31, 2020, it had a container fleet comprised 1,798,520 cost equivalent units. The company was formerly known as Container Applications International, Inc. and changed its name to CAI International, Inc. in February 2007. CAI International, Inc. was incorporated in 1989 and is headquartered in San Francisco, California.
Natera Inc.
Natera, Inc., a diagnostics company, develops and commercializes molecular testing services worldwide. It offers Panorama, a non-invasive prenatal test that screens for chromosomal abnormalities of a fetus with a blood draw from the mother, as well as twin pregnancies for zygosity; Vistara, a single-gene mutations screening test to identify single-gene disorder; Horizon carrier screening to determine carrier status for various genetic diseases; and Spectrum to analyze chromosomal anomalies or inherited genetic conditions during an in vitro fertilization cycle. The company also provides Anora miscarriage test products to analyze fetal chromosomes to understand the cause of miscarriage; and non-invasive paternity testing products to determine paternity by gestation using a blood draw from the pregnant mother and alleged father. In addition, it offers Constellation, a cloud-based software product that allows laboratory customers to gain access through the cloud to the company's algorithms and bioinformatics in order to validate and launch tests; Signatera, a circulating tumor DNA technology that screen for a generic set of mutations independent of an individual's tumor; and Prospera used to assess organ transplant rejection. The company offers products through its direct sales force, as well as through a network of approximately 100 laboratory and distribution partners. It has a partnership agreement with BGI Genomics Co., Ltd. to develop, manufacture, and commercialize NGS-based genetic testing assays; and Foundation Medicine, Inc. to develop and commercialize personalized circulating tumor DNA monitoring assays. The company was formerly known as Gene Security Network, Inc. and changed its name to Natera, Inc. in 2012. Natera, Inc. was founded in 2003 and is headquartered in San Carlos, California.
Latest CAI
- Amendment: SEC Form SCHEDULE 13G/A filed by Caris Life Sciences Inc.
- SEC Form 10-Q filed by Caris Life Sciences Inc.
- Caris Life Sciences Inc. filed SEC Form 8-K: Results of Operations and Financial Condition, Financial Statements and Exhibits
- Caris Life Sciences Reports Third Quarter 2026 Financial Results and Increases 2026 Revenue Guidance
- Caris Life Sciences Launches New National Commercial Featuring Jordan Spieth Highlighting the Power of Artificial Intelligence in Early Stage Cancer Detection
- Caris Life Sciences to Report Third Quarter 2026 Financial Results on November 4, 2026
- Caris Life Sciences to Present Eight Studies Highlighting the Power of AI, Multi-Omics and Precision Medicine at ESMO 2026
- Officer Denton John Russel sold $238,626 worth of shares (7,500 units at $31.82), decreasing direct ownership by 4% to 174,855 units (SEC Form 4)
- Officer Brille Brian J exercised 400,000 shares at a strike of $2.44 and sold $12,132,080 worth of shares (400,000 units at $30.33) (SEC Form 4)
- Caris Life Sciences Inc. filed SEC Form 8-K: Regulation FD Disclosure
Latest NTRA
- HLTH 2026 Names Natera Best-in-Class Winner in Cancer, Screening & Early Detection
- Amendment: SEC Form SCHEDULE 13G/A filed by Natera Inc.
- CO-FOUNDER Sheena Jonathan sold $478,945 worth of shares (1,500 units at $319.30) as part of a pre-agreed trading plan (SEC Form 4)
- SEC Form S-3ASR filed by Natera Inc.
- SEC Form S-8 filed by Natera Inc.
- CO-FOUNDER Sheena Jonathan sold $975,623 worth of shares (3,086 units at $316.14) as part of a pre-agreed trading plan and sold $19,781 worth of Common Stock (64 units at $309.08) as part of a pre-agreed trading plan, decreasing direct ownership by 1% to 214,462 units (SEC Form 4)
- Natera Announces Clinical Collaboration with Incyte on Interventional Phase II Study in Colorectal Cancer
- Amendment: SEC Form SCHEDULE 13G/A filed by Natera Inc.
- SEC Form 10-Q filed by Natera Inc.
- Natera Inc. filed SEC Form 8-K: Results of Operations and Financial Condition, Financial Statements and Exhibits